Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2020-04-27 Regulatory Filings
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(고형암 환자를 대상으로 'CBT101'의 내약성 및 안전성을 평가하는 임상1상 임상시험계획 신청)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Cha Biotech regarding the submission of a Phase 1 clinical trial application (IND) for 'CBT101' to the Ministry of Food and Drug Safety (MFDS). It details the clinical trial design, objectives, and potential risks. Since it is a specific regulatory announcement regarding company operations and clinical trial status that does not fit into categories like financial reports, dividends, or M&A, it is classified as a general regulatory filing.
2020-04-27 Korean
투자판단관련주요경영사항('퇴행성 요추 추간판으로 인한 만성 요통 환자'에 대한 'CordSTEM-DD' 임상 1/2a상 임상시험계획의 변경 승인 신청)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' (투자판단 관련 주요경영사항) disclosure. It details an application for a clinical trial plan amendment for a stem cell therapy (CordSTEM-DD). Since this is a specific regulatory disclosure regarding clinical trial status and does not fit into categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate disclosures.
2020-04-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and their special related parties, including specific transaction dates, methods (e.g., open market sales), and collateral agreements. This falls under the category of Major Shareholding Notification.
2020-04-17 Korean
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 97% confidence The document is a regulatory disclosure from Cha Biotech regarding the acquisition of a patent ('기타 경영사항(특허권 취득)'). It provides details on the patent name, content, and utilization plans. Since this is a specific regulatory disclosure of a corporate event that does not fit into financial reporting, dividend, or management change categories, it falls under the general regulatory filing category.
2020-04-08 Korean
사업보고서 (2019.12)
Audit Report / Information Classification · 95% confidence The document is a formal 'Audit Report' (감사보고서) for Cha Biotech (주식회사 차바이오텍) for the fiscal year 2019. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and notes. It is not an Annual Report (10-K) as it lacks the comprehensive management discussion and analysis (MD&A) and business overview typically found in a full 10-K, and it is not an Earnings Release as it is a full audited financial package. FY 2019
2020-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (AGM) for Cha Biotech, dated 2020-03-27. It details the outcomes of voting on agenda items such as financial statement approval, director and auditor appointments, and business purpose changes. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2020-03-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.